Your session is about to expire
← Back to Search
Ripretinib Drug Interaction Study for Gastrointestinal Stromal Tumor
Study Summary
This trial will look at how well the drug ripretinib works when taken with a CYP2C8 substrate.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have significant heart problems.I am 18 years old or older.My GIST has worsened or I couldn't tolerate 2 types of TKI treatments.I have been diagnosed with GIST.I have been treated with ripretinib before.I can take pills and do not have issues absorbing nutrients.I haven't taken repaglinide in the last 14 days.I haven't taken any cancer treatment or experimental drugs in the last 28 days.I have diabetes (type 1 or type 2).I can take care of myself and perform daily activities.My organs and bone marrow are working well.
- Group 1: Repaglinide 0.5 mg + Ripretinib 150 mg QD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings for participation in this research endeavor?
"Affirmative. Data on clinicaltrials.gov highlights that this medical trial, whose first posting was made on September 22nd 2021, is actively enrolling patients. A total of 30 participants are needed from three separate sites."
Has Ripretinib been evaluated in other clinical experiments?
"Ripretinib was first tested in 2021 at Renji Hospital, which is part of the Shanghai Jiaotong University School of Medicine. Since then 50 trials have been completed and 2 are ongoing around Portland, Oregon."
What purpose is Ripretinib usually prescribed for?
"Ripretinib is a treatment that can be leveraged for exercise, gastrointestinal stromal tumor (GIST) and therapeutic measures."
What is the cap on participants in this clinical examination?
"Affirmative. Clinicaltrials.gov provides evidence that this medical research is presently enrolling patients, with the first post having been made on September 22nd 2021 and its most recent update taking place November 17th 2022. Altogether, 30 individuals from 3 different centres need to be recruited for this experiment."
Has Ripretinib been verified by the FDA?
"Due to the limited clinical data available, our team at Power has assigned a score of 1 when ranking Ripretinib's safety relative to other medications. As this is still Phase 1 trial, more research is needed before any definitive conclusions can be made about its efficacy and potential risk factors."
Share this study with friends
Copy Link
Messenger